84 related articles for article (PubMed ID: 22005533)
1. HER-1, 2, and 3.
Gettinger S
J Thorac Oncol; 2011 Nov; 6(11 Suppl 4):S1793-6. PubMed ID: 22005533
[No Abstract] [Full Text] [Related]
2. Update on HER1-3 in advanced non-small-cell lung cancer.
Horn L; Lovly C
J Thorac Oncol; 2012 Dec; 7(16 Suppl 5):S369-71. PubMed ID: 23160321
[No Abstract] [Full Text] [Related]
3. Targeting the HER-kinase axis in cancer.
Gross ME; Shazer RL; Agus DB
Semin Oncol; 2004 Feb; 31(1 Suppl 3):9-20. PubMed ID: 15052539
[TBL] [Abstract][Full Text] [Related]
4. The HER3/ErbB3 receptor: a promising target in cancer drug therapy.
Desbois-Mouthon C
Gastroenterol Clin Biol; 2010; 34(4-5):255-9. PubMed ID: 20418034
[No Abstract] [Full Text] [Related]
5. Anti-epidermal growth factor receptor strategies for advanced breast cancer.
Campos SM
Cancer Invest; 2008 Oct; 26(8):757-68. PubMed ID: 18853311
[No Abstract] [Full Text] [Related]
6. ErbB receptors: directing key signaling networks throughout life.
Holbro T; Hynes NE
Annu Rev Pharmacol Toxicol; 2004; 44():195-217. PubMed ID: 14744244
[TBL] [Abstract][Full Text] [Related]
7. [Targeting epidermal growth factor receptor in cancer of the breast].
Diéras V; Pierga JY; Vincent-Salomon A; Beuzeboc P; Pouillart P; de Cremoux P
Bull Cancer; 2003 Nov; 90 Spec No():S257-62. PubMed ID: 14763149
[TBL] [Abstract][Full Text] [Related]
8. Targeting ADAMS and ERBBs in lung cancer.
Hynes NE; Schlange T
Cancer Cell; 2006 Jul; 10(1):7-11. PubMed ID: 16843261
[TBL] [Abstract][Full Text] [Related]
9. [Targeted therapies: the question of target detection and evaluation].
Penault-Llorca F
Bull Cancer; 2007; 94(7 Suppl):F245-8. PubMed ID: 17965004
[TBL] [Abstract][Full Text] [Related]
10. Foreword.
Chen HX; Cleck JN; Coelho R; Dancey JE
Curr Probl Cancer; 2009; 33(4):244. PubMed ID: 20082841
[No Abstract] [Full Text] [Related]
11. HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells.
Hirata A; Hosoi F; Miyagawa M; Ueda S; Naito S; Fujii T; Kuwano M; Ono M
Cancer Res; 2005 May; 65(10):4253-60. PubMed ID: 15899817
[TBL] [Abstract][Full Text] [Related]
12. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): simple drugs with a complex mechanism of action?
Normanno N; Maiello MR; De Luca A
J Cell Physiol; 2003 Jan; 194(1):13-9. PubMed ID: 12447985
[TBL] [Abstract][Full Text] [Related]
13. Tyrosine kinase signal transduction inhibitors. Clinical trials.
Scagliotti GV
Suppl Tumori; 2002; 1(4):S34-6. PubMed ID: 12415814
[No Abstract] [Full Text] [Related]
14. Targeted therapies: aiming for the bull's-eye.
Gaguski ME
ONS Connect; 2007 Jul; 22(7):8-12. PubMed ID: 17694778
[No Abstract] [Full Text] [Related]
15. Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu).
Reid A; Vidal L; Shaw H; de Bono J
Eur J Cancer; 2007 Feb; 43(3):481-9. PubMed ID: 17208435
[TBL] [Abstract][Full Text] [Related]
16. Targeting the epidermal growth factor receptor a new strategy in cancer treatment.
Gianni L; Grasselli G
Suppl Tumori; 2002; 1(4):S60-1. PubMed ID: 12415824
[No Abstract] [Full Text] [Related]
17. Regulation of ErbB receptor signalling in cancer cells by microRNA.
Barker A; Giles KM; Epis MR; Zhang PM; Kalinowski F; Leedman PJ
Curr Opin Pharmacol; 2010 Dec; 10(6):655-61. PubMed ID: 20864407
[TBL] [Abstract][Full Text] [Related]
18. Clinical trial design and end points for epidermal growth factor receptor-targeted therapies: implications for drug development and practice.
Arteaga CL; Baselga J
Clin Cancer Res; 2003 May; 9(5):1579-89. PubMed ID: 12738709
[No Abstract] [Full Text] [Related]
19. Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma.
Desbois-Mouthon C; Baron A; Blivet-Van Eggelpoël MJ; Fartoux L; Venot C; Bladt F; Housset C; Rosmorduc O
Clin Cancer Res; 2009 Sep; 15(17):5445-56. PubMed ID: 19706799
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of HER-2 inhibitors.
Rabindran SK
Cancer Lett; 2005 Sep; 227(1):9-23. PubMed ID: 16051028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
